SOMATEX^® is now part of Hologic!

Berlin, January, 2021 – With the acquisition of SOMATEX the medical company Hologic expands its tumor localiziation portfolio. “For years, SOMATEX has been committed to driving innovative, best-in-class tumor marker and localization solutions for our customers and their patients and to becoming a leader in our space,” said Joerg Heise, Managing Director of SOMATEX. “We are excited to continue this journey through Hologic and their global footprint, providing so many more with access to these pioneering technologies that aid in the early detection and treatment of breast cancer.”

Hologic and SOMATEX already have been business partners for years. Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions: “We’ve had a strong partnership with SOMATEX for several years, which along with our shared focus on innovation, will allow us to quickly integrate and begin building a pipeline that will drive profitable growth and recurring revenue for our breast health business globally.”